Extremely Volatile Plays Today: CREE, ACUR, ACRX, SNTS

Los Angelas, CA -- (SBWIRE) -- 03/05/2013 -- Cree Inc. (NASDAQ:CREE) raised its adjusted earnings guidance for the third quarter Tuesday morning to a range of $0.31 to $0.36 per share from the prior forecast in the $0.30 to $0.35 per share range. The company also raised its third-quarter revenue guidance to a range of $335 million to $350 million from the prior estimate between $325 million and $345 million. The consensus estimates are for EPS of $0.33 and revenues of $336.06 million. Cree gapped open sharply higher Tuesday and is now up 4.62 at $49.34 on above average volume. The stock has broken out of a 1-month trading range and has set a new high for the year.

How Should Investors Trade CREE Now? Find Out Here

Acura Pharmaceuticals Inc. (NASDAQ:ACUR) shares rose 21% to $2.49. The pharmaceutical company said Tuesday drug store chain Kerr Drug would stock its pseudoephedrine drug Nexafed. The company reported late Monday a fourth-quarter net loss that widened to $3 million, or 6 cents a share, from a year-ago loss of $1.6 million, or 3 cents a share. It had no quarterly revenue in either period.

Can ACUR Extend Rally? Find Out Here

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) jumped 5.62%; the company announced top-line data results demonstrating that the first of two pivotal placebo-controlled Phase 3 studies for its investigational sublingual Sufentanil NanoTab PCA (patient-controlled analgesia) System met its primary endpoint. Adverse events reported in the study were generally mild or moderate in nature and similar in both placebo and treatment groups.

Can ACRX Extend Gain? If Yes, How Far It Can Go? Find Out Here

Santarus Inc (NASDAQ:SNTS) shares climbed 14.71 percent to $15.79 in post-market trading Monday. The company reported fourth quarter net income of $0.08 per share after the close Monday, up from $0.03 per share in the previous year. The consensus estimate was for earnings per share of $0.01. The company expects to report full year 2013 EPS of $0.92 to $1.00, compared to the consensus estimate of $0.70.

Can SNTS Move Up Further? If Yes, How far It can Go? Find Out Here

Diclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com